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Introduction
Currently, chronic hepatitis C virus (HCV) infections are
the major cause of hepatocellular carcinoma (HCC) world-
wide (1). Therefore, an anti-HCV strategy is important for
the prevention of carcinogenesis. The treatment of HCV
with a combination of pegylated interferon (IFN) and
ribavirin is effective in 80% of HCV genotype 2 or 3 cases
but is less than 50% effective in genotype 1 cases. New
anti-HCV agents designed to inhibit the life cycle of HCV
have been developed and are used in combination with
IFN-α to ameliorate the salvage rate of HCV infection (2).
However, this combination therapy cannot completely elimi-
nate chronic HCV infections. Therefore, long-term man-
agement and safety drugs for chronic hepatitis C (CHC) pa-
tients are required.
Geranylgeranylacetone (GGA) is an isoprenoid compound,
which includes retinoids. GGA was developed in Japan and
has been used orally as an antiulcer drug (3). GGA protects
the gastric mucosa from various types of stress without af-
fecting gastric acid secretion (4,5). Moreover, GGA sup-
presses cell growth and induces differentiation or apoptosis
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Background. Geranylgeranylacetone (GGA), which is an isoprenoid compound, has been used orally as an antiulcer drug in
Japan. GGA induces antiviral gene expression by stimulating the formation of interferon-stimulated gene factor 3 in human
hepatoma cells. This study verified the anti-hepatitis C virus (HCV) activity of GGA in chronic hepatitis C-infected patients.
Methods. The present prospective study included 20 consecutive anti-HCV antibody-positive, HCV-genotype 1b, and chronic
gastritis patients who visited Nagasaki University Hospital between January 1999 and December 1999. GGA (150 mg per day,
which is the dose generally used for chronic gastritis) was taken orally for four weeks. We evaluated HCV-RNA titers and other
clinical parameters at pretreatment, posttreatment, and at the endpoint of the study. Pretreatment was the beginning point of
GGA treatment. Posttreatment was the termination point of GGA treatment. The endpoint was the point four weeks after the
posttreatment point.
Results. All patients completed four weeks of GGA treatment and four weeks of observation. HCV-RNA titers at postpoint
were not significantly diminished compared to those at pretreatment. However, HCV-RNA titers were significantly diminished
at endtreatment compared to pretreatment. Unfortunately, we did not observe a case with no titer of HCV-RNA. Alanine
aminotransferase values and other parameters were not affected by GGA treatment.
Conclusion. GGA has anti-HCV activities in chronic hepatitis C-infected patients. In the future, it will be necessary to examine
the clinical effectiveness of the combination of treatment with both GGA and interferon in HCV patients.
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in several human leukemia cells (6,7). 3,7,11,15-Tetramethyl-
2,4,6,-10,14-hexadecapentaenoic acid is another isoprenoid
compound that was designated as an acyclic retinoid be-
cause it has the ability to interact with nuclear retinoid re-
ceptors (8) that cause apoptosis in certain human hepatoma
cells (9). GGA acts as a potent inducer of antiviral gene ex-
pression, and it induces the expression by stimulating the
formation of IFN-stimulated gene factor 3 (ISGF3) in human
hepatoma cells (10). GGA induces the expression of antiviral
proteins such as 2′5′-oligoadenylate synthetase (2′5′-OAS)
and double-stranded RNA-dependent protein kinase (PKR)
in hepatoma cell lines. GGA stimulates 2′5′-OAS and PKR
gene expression at the transcriptional level through the for-
mation of ISGF-3, which regulates the transcription of both
genes. GGA induces the expression of signal transducers
and activators of transcription 1, 2 (STAT-1, STAT-2) and
p48 proteins, components of ISGF3, together with the
phosphorylation of STAT1 (10). However, the anti-HCV
activity of GGA has not been observed in vivo and in vitro.
At present, new treatments for CHC patients are neces-
sary, and GGA has an IFN-like action in hepatoma cells
(10). Therefore, we attempted to verify the anti-HCV activ-
ity of GGA in CHC patients.
Methods
Patients
The present prospective study included 20 consecutive
anti-HCV antibody-positive, HCV-genotype 1b, and chronic
gastritis patients who visited the Nagasaki University Hospital
between January 1999 and December 1999. Patients were
enrolled in the study after informed consent was obtained.
The patients had not been previously treated with IFN ther-
apy and were diagnosed with CHC on the basis of clinical
data. The patients were evaluated with a HCV-RNA polymerase
chain reaction (PCR) method (Amplicor method). The
HCV-RNA high group (100,000 IU/mL or more in the
serum) was identified by quantitative PCR. The criteria for
HCC were assessed by abdominal imaging methods and by
HCC history. The patients who were not previously diag-
nosed with diabetes mellitus (DM) were evaluated by the
75-g oral glucose tolerance test (OGTT). All subjects un-
derwent OGTT with 75 g of glucose according to the rec-
ommendations of the National Diabetes Data Group of the
National Institute of Health. Blood samples were taken at 0,
30, 60, 90, 120, and 180 min after administration in order to
measure the plasma glucose (PG) and insulin concentrations.
In this study, the DM group consisted of patients with clini-
cally diagnosed DM or 110 mg/dL fasting PG and/or 140
mg/dL or high PG at 120 min.
White blood cell counts, red blood cell counts, platelet
counts, hemoglobin A1c levels, alanine aminotransferase
(ALT) levels, aspartate aminotransferase (AST) levels, and
γ-glutamyl transpeptidase (GTP) levels were determined
by hematometry and standard laboratory techniques. Clinical
characteristics are shown in the Table.g
Methods
The dose of 150 mg of GGA per day, which is generally
used to treat chronic gastritis in Japan, was taken orally for
four weeks, and it was assumed that patients took one dose
a day. Pretreatment was the beginning point of GGA treat-
ment. We evaluated HCV-RNA titers and other clinical pa-
rameters at pretreatment, posttreatment, and study end-
point. Posttreatment was the termination point of GGA
treatment. Endpoint was the point four weeks after the
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HCV high titer 14
HCV-RNA titer 489 (378)
HCC +/- 0/20
WBC count 6004 (1585)
RBC count 447 (60)
Plt count 18.9 (7.9)
Alb level 4.46 (3.0)
AST level 49.5 (21.2)
ALT level 71 (28)
γ-GTP level 50.5 (32)
DM +/- 0/20
HbA1c level 5.05 (0.8)
FPG level 96 (13)
Table. Clinical characteristics at pre-GGA treatment
Characteristic mean (SD) or number
Data are shown as means (standard deviation) and numbers.
BMI, body mass index; HCV, Hepatitis C virus; HCC, hepatocellular car-
cinoma; WBC, white blood cells; RBC, red blood cells; Plt, platelets; Alb,
albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase;
γ-GTP,γ-glutamyl transpeptidase; DM, diabetes mellitus; HbA1c, hemo-
globin A1c; FPG, fasting plasma glucose.
Normal values in laboratory tests: ALT (IU/L), 5-40; AST (IU/L), 10-40;
γ-GTP (IU/L), <70 in men, <30 in women; Alb (g/dL), 4.0-5.0; WBC
(cells/μL), 3500-9000; RBC (× 104 cells/μL), 450-580 in men, 380-480
in women; Plt (× 104 platelets/μL), 14-33; ferritin (ng/mL), 39.4-340 in
men, 3.6-114 in women; FPG (mg/dL), 70-110; HbA1c (%), 4.3-5.8; BMI,
body weight (kg)/height2 (m).
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posttreatment of GGA. During this study, all patients were
not treated with Stronger Neo-Minophagen C (Minophagen
Pharmaceutical Co., Ltd., Tokyo, Japan) because of its anti-
hepatitis effects or with IFN because of its anti-HCV effects.
Statistical analysis
Data were processed on a personal computer and ana-
lyzed using StatView 5.0 (SAS Institute, Inc., Cary, NC).
The differences in the values of each laboratory parameter
were analyzed with a t-test. P values less than 0.05 were
considered statistically significant.
Results
GGA decreased the HCV-RNA titers in patients but did not
affect the values of ALT
All patients completed four weeks of GGA treatment and
four weeks of observation. Adverse effects were not observed
in any patient. The titers of HCV-RNA (Fig. 1A) changed
after the patients completed GGA treatment. Compared
with HCV-RNA titers at pretreatment, titers at endpoint did
not diminish significantly. However, compared to HCV-
RNA titers at pretreatment, the titers were significantly di-
minished at posttreatment. Unfortunately, we did not ob-
serve a case with no titer of HCV-RNA. Values of ALT
(Fig. 1B) and other parameters were not changed by GGA
treatment. The diminished HCV-RNA titers at the posttreatment
point were increased at the endpoint, which was four weeks
after the posttreatment point.
In Fig. 2, we present the case of a patient who had the
most diminished HCV-RNA titers among the 20 GGA-
treated patients (Fig. 2). This case had mild fluctuations of
ALT levels before GGA treatment. The HCV-RNA titer
was 420 K copies/mL and 380 K copies/mL at 12 weeks
before treatment and at the pretreatment point, respectively.
After GGA treatment, HCV-RNA titers were decreased to
2 K copies/mL and 4 K copies/mL at the endpoint and at
the posttreatment point, respectively. In this case, the ALT
values were also diminished in a similar manner as HCV-
RNA. After the observation period, +12 weeks, HCV-RNA
titers and ALT values were increased compared to those at
the pretreatment point.
Discussion
GGA demonstrated anti-HCV activity in this study. The
anti-HCV effect that was due to GGA did not result in a
disappearance of HCV-RNA titers in CHC patients. An ad-
verse effect was not observed with GGA treatment.
GGA is a non-toxic heat shock protein (HSP) 70 inducer
(11). Various GGA activities outside of the stomach are
also related to HSP induction (12,13,14). GGA induces
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Figure 1. Titers of hepatitis C virus (HCV)-RNA at the endpoint
were decreased compared to the levels at pretreatment (A), but
alanine aminotransferase (ALT) levels were not changed (B).
Panel A shows serum HCV-RNA titers, and panel B shows serum
ALT levels at each of the indicated points. The bar indicates the
mean value. Statistical significance was accepted with p-values less
than 0.05. "Pre" indicates the point of pre-geranylgeranylacetone
(GGA) treatment. "Post" indicates the termination point of GGA
treatment. "End" indicates the point four weeks after posttreatment
of GGA. Compared to HCV-RNA titers at pretreatment, GGA
treatment decreased the titer at pretreatment but not at posttreatment.
Figure 2. The clinical course of a geranylgeranylacetone (GGA)-
treated chronic hepatitis C (CHC) patient.
Here, we present a case of a 53-year-old man who was an out-
patient of our hospital for 5 years. He was diagnosed with chronic
hepatitis on the basis of clinical data. The patient had not been
previously treated with interferon (IFN). The y-axis indicates alanine
aminotransferase (ALT) levels, and the x-axis indicates the time
course. The duration of the GGA treatment periods is shown in
the gray field. The zero point on the x-axis is the GGA treatment-
starting day. HCV-RNA titers are 420, 380, 2, and 4 K copies/mL
at -12 weeks, 0 weeks (pretreatment), +4 weeks (posttreatment),
and +8 weeks (end of follow-up period), respectively.
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thioredoxin, as well as HSP-70, in hepatocytes and other
cells (15). The antiviral activity of thioredoxin is induced
by AP-1 and NF-κB but not by HSP-70 (16). GGA, which
has potent antiviral activities through the enhancement of
antiviral factors, can clinically provide protection from in-
fluenza viral infections (17). Previously, we reported that
GGA induction of antiviral proteins was dependent upon
STAT-1 tyrosine phosphorylation in HuH-7 and HepG2
with which HCV was not infected (10). However, HCV
products inhibit the Jak-STAT pathway in HCV-infected
hepatocytes (18). The mechanism of inhibition of the Jak-
STAT pathway is multifactorial and includes the expres-
sion of suppressor of cytokine signaling 3 (SOCS-3) (19),
protein phosphatase 2A induction (20), STAT-3 expression
(21), and IL-8 expression (22). A clarification of GGA-
induced anti-HCV activity is necessary for further exami-
nation of the in vitro and in vivo effects.
The peak venous blood concentration after taking 150
mg of GGA orally is 5-7μmol/L (23), but 50μmol/L is the
best dose for induction of PKR and 2′5′-OAS in hepatoma
cell lines (10). In this study, we employed the usual dosage
of GGA used to treat chronic gastritis in Japan, which is
150 mg per day. In a previous study, it was reported that
portal blood concentration after taking 150 mg of GGA
orally was several-fold that of the venous blood concentra-
tion (23). The usual dosage of GGA also may have a possi-
ble antiviral gene expression effect in the liver.
In conclusion, GGA, a drug that can be safely adminis-
tered orally, has anti-HCV activity. Unfortunately, we did
not observe a case that exhibited disappearance of HCV-
RNA titers. GGA treatment is insufficient for clearance of
HCV, and, therefore, it will be necessary to examine the
clinical effectiveness of the combination treatment with
GGA and IFN in HCV patients in the future.
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